Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02629692
Title Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing >/=3 Prior CML Therapies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Sun Pharma Advanced Research Company Limited

acute lymphoblastic leukemia

chronic myeloid leukemia



Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | BEL

Additional content available in CKB BOOST